List of Excipients in Branded Drug GLYSET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia and Upjohn Company LLC	GLYSET	miglitol	0009-5012	CELLULOSE, MICROCRYSTALLINE
Pharmacia and Upjohn Company LLC	GLYSET	miglitol	0009-5012	HYPROMELLOSE
Pharmacia and Upjohn Company LLC	GLYSET	miglitol	0009-5012	MAGNESIUM STEARATE
Pharmacia and Upjohn Company LLC	GLYSET	miglitol	0009-5012	POLYETHYLENE GLYCOL
Pharmacia and Upjohn Company LLC	GLYSET	miglitol	0009-5012	POLYSORBATE 80
Pharmacia and Upjohn Company LLC	GLYSET	miglitol	0009-5012	STARCH, CORN
Pharmacia and Upjohn Company LLC	GLYSET	miglitol	0009-5012	TITANIUM DIOXIDE

GLYSET (Miglitol) Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

GLYSET is the U.S. brand for miglitol, an oral alpha-glucosidase inhibitor supplied as immediate-release tablets in 25 mg, 50 mg, and 100 mg strengths. The commercial opportunity is primarily a low-cost generic or differentiated oral solid product, not a biologic or biosimilar program. The core formulation is relatively simple, but launch economics depend on bioequivalence, tablet manufacturability, current Orange Book status, and competition from metformin, acarbose, GLP-1 therapies, and other antihyperglycemic drugs.

What formulation does GLYSET use?

GLYSET is an immediate-release tablet intended to be taken orally with the first bite of each main meal. The labeled strengths are 25 mg, 50 mg, and 100 mg. The approved dosing range generally begins at 25 mg three times daily and may increase to 100 mg three times daily, subject to tolerability and renal function considerations. [1]

The U.S. product label identifies the following inactive ingredients:

Excipient	Functional role
Microcrystalline cellulose	Diluent, compression aid, tablet structure
Povidone	Binder and granulation aid
Starch	Diluent and disintegrant
Magnesium stearate	Lubricant

The formulation is consistent with a conventional wet- or dry-granulated immediate-release tablet. Its main development challenge is not complex drug delivery. It is achieving rapid and reproducible tablet breakup, dissolution, content uniformity, and mechanical strength across three dose strengths.

What are the key physical and chemical properties of miglitol?

Miglitol is an iminosugar with high polarity and substantial water solubility. The active ingredient is administered at relatively low tablet loads, particularly in the 25 mg and 50 mg strengths. These characteristics support direct compression or a simple granulation process, subject to powder-flow and segregation data.

The formulation must account for:

• High active-ingredient polarity and potential hygroscopicity.
• Low-dose content-uniformity risk in the 25 mg strength.
• Lubricant sensitivity, particularly excessive magnesium stearate.
• Rapid dissolution requirements for an immediate-release product.
• Dose proportionality across 25 mg, 50 mg, and 100 mg tablets.
• Renal clearance and the need to avoid formulation changes that alter exposure materially.

Miglitol is not designed as a sustained-release product. Its pharmacologic effect depends on intestinal enzyme inhibition during carbohydrate absorption. A delayed- or extended-release dosage form would require separate clinical and regulatory justification.

Which excipients are best for a generic GLYSET tablet?

The lowest-risk strategy is a Q1/Q2-oriented formulation that preserves the approved excipient classes and, where practical, the qualitative and quantitative composition of the reference product. FDA inactive-ingredient precedents and the reference product labeling should guide excipient selection. [2]

Recommended excipient platform

Formulation function	Base option	Alternative options	Key development issue
Diluent	Microcrystalline cellulose	Mannitol, lactose, dibasic calcium phosphate	Flow, compactability, moisture exposure
Binder	Povidone	Hydroxypropyl cellulose, pregelatinized starch	Granule strength and dissolution
Disintegrant	Starch	Croscarmellose sodium, crospovidone, sodium starch glycolate	Disintegration at high compression force
Lubricant	Magnesium stearate	Sodium stearyl fumarate	Over-lubrication and dissolution delay
Glidant	Not necessarily required	Colloidal silicon dioxide	Flow improvement and blend uniformity
Film coat	Optional	Hypromellose-based system	Identification, swallowability, moisture barrier

A formulation using microcrystalline cellulose, povidone, starch, and magnesium stearate offers the clearest regulatory and manufacturing path. Substitution with mannitol or lactose may improve mouthfeel or compactability but can introduce new moisture, flow, or compatibility variables.

How should the 25 mg strength be formulated?

The 25 mg tablet presents the greatest content-uniformity risk because the active represents a smaller percentage of total tablet weight. A robust process would use controlled premixing, geometric dilution, validated blend sampling, and a particle-size strategy that limits segregation.

Potential approaches include:

1. A common granulation formula scaled across all strengths.
2. A proportionally similar tablet weight across strengths.
3. A high-shear granulation process to reduce active-excipient segregation.
4. Controlled milling of the active and excipient blend.
5. A validated hold-time program for lubricated blends.

A single proportional composition can simplify manufacturing and reduce inventory. Separate strength-specific formulas may improve tablet size and patient usability but increase process complexity.

What excipient risks affect GLYSET generic development?

The largest risk is dissolution failure caused by over-lubrication or excessive tablet hardness. Magnesium stearate is effective at low concentrations, but longer blending times and higher lubricant levels can create hydrophobic particle coatings that delay wetting and dissolution.

Starch can support rapid disintegration, but its performance varies by botanical source, moisture, particle size, and grade. Povidone can improve granule strength but may increase granule density and slow disintegration if used excessively.

Key compatibility studies

A development program should assess:

• Miglitol assay and degradation under heat and humidity.
• Water activity and hygroscopicity.
• Compatibility with magnesium stearate, povidone, starch, and cellulose.
• Blend uniformity at the 25 mg strength.
• Tablet tensile strength versus disintegration time.
• Dissolution across multiple pH conditions.
• Stability in high-density polyethylene and blister packaging.
• Extractables and leachables for coated or blistered products.

Packaging is a commercial variable. A standard HDPE bottle may provide the lowest cost, while a moisture-barrier blister may offer better stability and unit-dose adherence. The appropriate choice depends on stability data and target-market requirements.

What FDA pathway applies to a generic GLYSET product?

A conventional generic miglitol tablet would generally be developed through an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The reference product is GLYSET, associated with NDA 020975 in FDA product records. [1,3]

The principal requirements are:

• Pharmaceutical equivalence.
• Bioequivalence.
• Conformance to current good manufacturing practice.
• Adequate stability data.
• Appropriate labeling.
• Demonstration that the formulation does not introduce an unacceptable inactive-ingredient risk.

For an immediate-release oral product, the sponsor would normally rely on comparative dissolution and pharmacokinetic bioequivalence. A reformulated product with materially different release characteristics could fall outside the normal ANDA pathway.

FDA’s product-specific guidance, if applicable, should control study design, fasting and fed conditions, and the number of strengths requiring clinical pharmacokinetic testing. [3]

What patents protect GLYSET and when does miglitol lose exclusivity?

The original composition and product exclusivity for miglitol are long expired. GLYSET was approved in the United States in 1996, placing the product well beyond its original small-molecule patent and five-year new chemical entity exclusivity periods. [1,3]

Current commercial protection should be analyzed through the FDA Orange Book and relevant national patent registers. The main issues are:

Protection category	Relevance to miglitol
Original compound patent	Expected to be expired
New chemical entity exclusivity	Expired
Original tablet formulation patents	Expected to be expired or commercially inactive
Method-of-use patents	Must be checked for any surviving listed claims
Manufacturing patents	Could affect process design but may not block a conventional ANDA
Pediatric exclusivity	Not expected to provide current market protection
Orphan exclusivity	Not applicable to the standard GLYSET indication

A generic sponsor should distinguish between patents listed for the reference product and broader third-party patents covering manufacturing processes, crystalline forms, impurity controls, or alternative dosage forms.

Is there a Paragraph IV risk for GLYSET?

A Paragraph IV certification is relevant only if the current Orange Book lists an unexpired patent that the ANDA sponsor believes is invalid, unenforceable, or not infringed. Because the core GLYSET exclusivity period is historical, the principal risk is not the original miglitol patent. It is a later-listed formulation, use, or manufacturing patent, if one remains active.

A conventional immediate-release tablet using established excipients is less likely to infringe a narrowly drafted controlled-release, abuse-deterrent, taste-masked, or combination-product patent. Process changes still require freedom-to-operate review because manufacturing patents can create litigation exposure even when they do not block FDA approval.

What formulation patents could create commercial differentiation?

The strongest formulation opportunities are outside the basic GLYSET tablet composition.

Modified-release miglitol

A modified-release product could attempt to align intestinal miglitol exposure with meals, reduce gastrointestinal adverse effects, or improve adherence. The commercial case is uncertain because patients generally take immediate-release miglitol with meals and the mechanism requires drug presence during carbohydrate digestion.

Modified-release technology could create patentable claims around:

• Polymer matrices.
• Enteric or delayed-release coatings.
• Multiparticulate beads.
• Site-specific intestinal release.
• Meal-triggered release.
• Reduced peak intestinal concentration.

The regulatory burden would be higher than for a conventional generic and might require clinical efficacy or comparative pharmacodynamic data.

Chewable, orally disintegrating, or sprinkle products

A chewable or orally disintegrating tablet could target patients with swallowing difficulties. Miglitol’s high solubility may support rapid-disintegration formats, but taste is a central development issue.

Possible excipient systems include:

• Mannitol for mouthfeel.
• Crospovidone or croscarmellose for rapid disintegration.
• Sucralose or aspartame for sweetness.
• Flavors and cooling agents.
• Ion-exchange resins or polymeric taste-masking systems.

Taste masking may add patent value, but it can also delay dissolution or create dose-uniformity issues. A product intended to be taken with meals would need clear administration instructions to avoid confusion between swallowing and chewing.

Fixed-dose combinations

Miglitol could theoretically be combined with metformin or another antihyperglycemic. The commercial rationale is limited by differing dosing schedules, gastrointestinal tolerability, renal restrictions, and the availability of inexpensive generic alternatives.

A combination product would face:

• New dose-selection work.
• Compatibility and stability studies.
• Additional clinical bridging.
• More complex labeling.
• Greater risk that one component limits use of the entire product.

The more practical combination opportunity may be a co-packaged regimen rather than a single tablet.

How does GLYSET compare with competing diabetes products?

Miglitol competes primarily on mechanism and price rather than convenience. It inhibits intestinal alpha-glucosidases and is used with meals. Its main disadvantages are gastrointestinal adverse effects and three-times-daily dosing.

Product class	Dosing convenience	Generic pressure	Commercial implication
Miglitol	Usually three times daily with meals	High	Low-cost niche generic
Acarbose	Usually three times daily with meals	High	Direct mechanistic competitor
Metformin	Once or twice daily depending on formulation	Very high	Strong price and prescribing benchmark
DPP-4 inhibitors	Once daily for many products	Moderate to high	Better convenience
GLP-1 receptor agonists	Weekly or daily depending on product	Variable	Strong efficacy and weight-loss positioning
SGLT2 inhibitors	Once daily	Increasing	Cardiovascular and renal differentiation

A miglitol product is most commercially attractive where physicians still use alpha-glucosidase inhibition, where low acquisition cost matters, or where local treatment guidelines support the class.

Which companies are likely to challenge GLYSET?

The likely challengers are generic manufacturers with established oral-solid manufacturing and ANDA infrastructure. Miglitol does not require biosimilar development, sterile manufacturing, or complex-device integration for a standard tablet.

Potential commercial entrants would compete on:

• Low-cost API sourcing.
• Three-strength portfolio coverage.
• Reliable supply.
• Bottle and blister packaging options.
• Private-label distribution.
• Multi-country registration.
• Contract manufacturing capacity.

A single-strength launch may reduce initial cost but weaken formulary and pharmacy substitution opportunities. A complete 25 mg, 50 mg, and 100 mg portfolio is more commercially useful.

What geographic opportunities exist for miglitol products?

The United States offers a straightforward generic pathway but may have limited market volume. Other markets can present opportunities where alpha-glucosidase inhibitors remain standard components of type 2 diabetes treatment.

Commercial screening should prioritize:

• Countries with established miglitol or alpha-glucosidase inhibitor use.
• Markets with local generic substitution.
• Regions with high prevalence of postprandial hyperglycemia.
• Countries where imported branded products remain expensive.
• Jurisdictions accepting well-established immediate-release tablet data packages.

Patent status, reference-product availability, local bioequivalence requirements, and reimbursement differ by jurisdiction. A formulation optimized for the United States may require different packaging, excipient documentation, or strength registration elsewhere.

What is the commercial value of an excipient-focused GLYSET strategy?

The most defensible strategy is a low-risk immediate-release generic with a familiar excipient system, efficient three-strength manufacturing, and packaging selected for stability and cost.

Higher-value opportunities include:

1. A taste-masked orally disintegrating product.
2. A chewable formulation for dysphagia or administration flexibility.
3. A low-moisture, high-stability tablet for emerging markets.
4. A unit-dose blister product for meal-linked adherence.
5. A co-packaged diabetes regimen.
6. A differentiated tablet with improved gastrointestinal tolerability, if supported clinically.

The market is unlikely to support a highly complex formulation unless it solves a clear adherence, tolerability, or access problem. The strongest near-term economics are likely in manufacturing efficiency, geographic expansion, and reliable supply rather than in expensive delivery technology.

Key Takeaways

• GLYSET is an immediate-release miglitol tablet in 25 mg, 50 mg, and 100 mg strengths.
• The labeled excipients are microcrystalline cellulose, povidone, starch, and magnesium stearate.
• A Q1/Q2-oriented formulation is the lowest-risk generic strategy.
• The 25 mg strength creates the greatest blend-uniformity and segregation risk.
• Excess magnesium stearate or excessive tablet hardness can delay dissolution.
• Miglitol’s original small-molecule exclusivity is historical; current Orange Book listings must control any Paragraph IV analysis.
• Modified-release, chewable, orally disintegrating, and taste-masked products offer the clearest formulation-patent opportunities.
• A conventional generic is more commercially credible than a high-cost novel delivery system.
• The principal competitive risks are low generic pricing, three-times-daily dosing, gastrointestinal adverse effects, and competition from newer diabetes therapies.
• There is no biosimilar pathway issue because miglitol is a synthetic small molecule.

FAQs

Can lactose replace microcrystalline cellulose in a generic GLYSET tablet?

Yes, lactose may be technically suitable, but the substitution can change moisture behavior, compactability, dissolution, and stability. The formulation must remain within applicable FDA inactive-ingredient and ANDA requirements.

Is a GLYSET orally disintegrating tablet commercially attractive?

It could address swallowing difficulty, but taste masking is likely to determine feasibility. Miglitol’s meal-linked administration makes rapid disintegration useful, but not sufficient to create demand without a clear tolerability or adherence benefit.

Does miglitol require a controlled-release formulation?

No. The approved product is immediate release, and its pharmacologic effect occurs during intestinal carbohydrate digestion. Controlled release would require a separate product-development and regulatory strategy.

What is the most important manufacturing risk for miglitol tablets?

The principal risks are low-dose blend uniformity, powder segregation, over-lubrication, and dissolution delay caused by excessive compression or hydrophobic lubricant coverage.

Can a generic company launch only the 100 mg GLYSET strength?

A single-strength launch may be legally and technically possible, but it limits prescribing and substitution flexibility. A three-strength portfolio is generally more commercially useful for pharmacy and payer coverage.

References

1. U.S. Food and Drug Administration. (1996). GLYSET (miglitol) tablets prescribing information, NDA 020975.
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2015). ANDA submissions: Content and format of an abbreviated new drug application.
5. International Council for Harmonisation. (2003). ICH Q8(R2): Pharmaceutical development.